Date printed: 12/01/2019
NeisVac-C
Details for NeisVac-C vaccine and its components.
Sponsor:
Pfizer Australia
Administration route:
Intramuscular injection
Vaccine group:
Monovalent meningococcal C vaccine
Registered for use in children aged ≥8 weeks and in adults.
MenC — monovalent meningococcal serogroup C–tetanus toxoid conjugate vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- 10 µg Neisseria meningitidis serogroup C
- 10–20 µg tetanus toxoid protein
Adsorbed onto 1.4 mg aluminium hydroxide.
The product information and consumer medicine information for NeisVac-C have more details.
Audience:
Infants and children
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
This document was printed on: 24/01/2019. Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/neisvac-c.